{ "FullStudy":{ "Rank":217835, "Study":{ "ProtocolSection":{ "IdentificationModule":{ "NCTId":"NCT01516216", "OrgStudyIdInfo":{ "OrgStudyId":"11-436" }, "Organization":{ "OrgFullName":"Dana-Farber Cancer Institute", "OrgClass":"OTHER" }, "BriefTitle":"Study of Vitamin D in Untreated Metastatic Colorectal Cancer", "OfficialTitle":"Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer" }, "StatusModule":{ "StatusVerifiedDate":"December 2019", "OverallStatus":"Completed", "ExpandedAccessInfo":{ "HasExpandedAccess":"No" }, "StartDateStruct":{ "StartDate":"April 13, 2012", "StartDateType":"Actual" }, "PrimaryCompletionDateStruct":{ "PrimaryCompletionDate":"November 9, 2019", "PrimaryCompletionDateType":"Actual" }, "CompletionDateStruct":{ "CompletionDate":"November 9, 2019", "CompletionDateType":"Actual" }, "StudyFirstSubmitDate":"January 13, 2012", "StudyFirstSubmitQCDate":"January 23, 2012", "StudyFirstPostDateStruct":{ "StudyFirstPostDate":"January 24, 2012", "StudyFirstPostDateType":"Estimate" }, "LastUpdateSubmitDate":"December 12, 2019", "LastUpdatePostDateStruct":{ "LastUpdatePostDate":"December 16, 2019", "LastUpdatePostDateType":"Actual" } }, "SponsorCollaboratorsModule":{ "ResponsibleParty":{ "ResponsiblePartyType":"Principal Investigator", "ResponsiblePartyInvestigatorFullName":"Kimmie Ng, MD", "ResponsiblePartyInvestigatorTitle":"Principal Investigator", "ResponsiblePartyInvestigatorAffiliation":"Dana-Farber Cancer Institute" }, "LeadSponsor":{ "LeadSponsorName":"Dana-Farber Cancer Institute", "LeadSponsorClass":"OTHER" } }, "OversightModule":{ "OversightHasDMC":"Yes" }, "DescriptionModule":{ "BriefSummary":"The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor in the cancer cells, it may stop cancer cells from growing abnormally and may cause cell death. Vitamin D has been used in other research studies and information from those other research studies suggests that Vitamin D may help in the treatment of colorectal cancer.\n\nIn this research study, the investigators are comparing standard and higher dose Vitamin D treatment when given in combination with standard treatment for metastatic colorectal cancer. Standard treatment includes the chemotherapy combination of 5-FU, Leucovorin and Oxaliplatin (FOLFOX) with bevacizumab.", "DetailedDescription":"Participants will be randomized into one of the study groups-Arm A: Vitamin D (standard dose of 400 IU/day), FOLFOX and Bevacizumab or Arm B: Vitamin D (higher dose of 8000 IU/day for 2 weeks followed by 4000 IU/day), FOLFOX and Bevacizumab.\n\nStudy Treatment (A cycle of treatment is 14 days):\n\nVitamin D\n\nCycle 1: You will take two capsules of Vitamin D orally, once a day (at the same time), every day. Participants randomized to Arm A will be taking one capsule with 400 IU of Vitamin D and one capsule with placebo (pills with no medicine) so that neither you nor your doctor will know what group you have been assigned to. Participants randomized to Arm B will be taking two capsules of 4000 IU each.\n\nSubsequent Cycles: You will take one capsule orally, once a day (at the same time), every day. Participants randomized to Arm A will be taking one capsule with 400 IU of Vitamin D. Participants randomized to Arm B will be taking one capsule with 4000 IU of Vitamin D.\n\nFOLFOX and bevacizumab\n\nFOLFOX and bevacizumab will be given intravenously (IV, through a vein in your arm) on Day 1 of every cycle for all participants in both Arms A and B. The infusions will take several hours, in addition to your doctor's visit, so you should plan on being in clinic most of the day. Note that the 5-FU is given bolus on day 1 (given as one dose), and is then given as a continuous IV infusion over 2 days. You will need to have a port-a-cath placed. A port-a-cath is a medical device that is placed under the skin. The continuous infusion is delivered by a pump that is inserted into the port-a-cath. The pump will be carried in a pouch that you can hook around your waist. Arrangements will be made for you to have the pump disconnected after 2 days. You may need to return to clinic to have it disconnected.\n\nWhile on study, the following tests and procedures will be performed:\n\nCycle 1, Day 1\n\nQuestions about your health, current medications and any allergies.\nPhysical exam, including vital signs\nPerformance status\nRoutine blood tests to evaluate your health\nUrine test\n\nSubsequent Cycles, Day 1\n\nQuestions about your health, current medications, allergies and any side effects you may be having.\nPhysical exam, including vital signs\nPerformance status\nRoutine blood tests to evaluate your health\nUrine test\nReview of your study drug diary (please bring with you every visit).\n\nEvery 4 cycles (approximately every 8 weeks): An assessment of your tumor by CT scan or MRI.\n\nAdditional blood samples for research: Samples will be drawn (a little more than 1 teaspoon of blood) after Cycle 4, Cycle 8 and then every 8 Cycles thereafter.\n\nYou will continue to receive treatment as long as your disease does not get worse and you are tolerating the treatment.\n\nEnd of treatment\n\nQuestions about your health, current medications and any allergies.\nPhysical exam, including vital signs\nPerformance status\nBlood tests (routine blood tests to evaluate your health and a blood sample for research)\nUrine test\nAn assessment of your tumor by CT scan or MRI\n\nAfter the final dose of the study drug:\n\nYou will be followed for safety reasons for 30 days after the last dose of study drug. If you are experiencing side effects, you may continue to be followed until the side effects resolve or until you start another treatment.\n\nIf you discontinue study treatment for reasons other than disease progression (for example, side effects), you will be asked to continue to get tumor assessments every 8 - 16 weeks until your disease worsens as demonstrated by a tumor assessment or until you start another therapy to treat your cancer. These assessments may coincide with your routine follow-up, in which case they would not need to be repeated.\n\nWe would like to keep track of your medical condition for the rest of your life. We would like to do this by reviewing your medical records and/or by calling you on the telephone every 3 months to see how you are doing. Keeping in touch with you and checking on your condition helps us look at the long-term effects of the research study." }, "ConditionsModule":{ "ConditionList":{ "Condition":[ "Metastatic Colorectal Cancer" ] }, "KeywordList":{ "Keyword":[ "previously untreated" ] } }, "DesignModule":{ "StudyType":"Interventional", "PhaseList":{ "Phase":[ "Phase 2" ] }, "DesignInfo":{ "DesignAllocation":"Randomized", "DesignInterventionModel":"Parallel Assignment", "DesignPrimaryPurpose":"Treatment", "DesignMaskingInfo":{ "DesignMasking":"Triple", "DesignWhoMaskedList":{ "DesignWhoMasked":[ "Participant", "Care Provider", "Investigator" ] } } }, "EnrollmentInfo":{ "EnrollmentCount":"139", "EnrollmentType":"Actual" } }, "ArmsInterventionsModule":{ "ArmGroupList":{ "ArmGroup":[ { "ArmGroupLabel":"Standard Dose Vitamin D", "ArmGroupType":"Active Comparator", "ArmGroupDescription":"Standard Dose Vitamin D with Bevacizumab and FOLFOX. FOLFOX contains: 5-FU (5-fluorouracil), Leucovorin and Oxaliplatin (Eloxatin).", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: FOLFOX + bevacizumab", "Dietary Supplement: Vitamin D" ] } },{ "ArmGroupLabel":"Higher Dose Vitamin D", "ArmGroupType":"Active Comparator", "ArmGroupDescription":"Higher Dose Vitamin D with Bevacizumab and FOLFOX. FOLFOX contains: 5-FU (5-fluorouracil), Leucovorin and Oxaliplatin (Eloxatin).", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: FOLFOX + bevacizumab", "Dietary Supplement: Vitamin D" ] } } ] }, "InterventionList":{ "Intervention":[ { "InterventionType":"Drug", "InterventionName":"FOLFOX + bevacizumab", "InterventionDescription":"Given intravenously on Day 1 of every cycle", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "Higher Dose Vitamin D", "Standard Dose Vitamin D" ] }, "InterventionOtherNameList":{ "InterventionOtherName":[ "5-FU (5-fluorouracil)", "Leucovorin", "Oxaliplatin (Eloxatin)", "Bevacizumab (Avastin)" ] } },{ "InterventionType":"Dietary Supplement", "InterventionName":"Vitamin D", "InterventionDescription":"Standard Dose (400 IU once daily)", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "Standard Dose Vitamin D" ] } },{ "InterventionType":"Dietary Supplement", "InterventionName":"Vitamin D", "InterventionDescription":"Higher Dose (8000 IU once daily for 2 weeks, followed by 4000 IU once daily)", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "Higher Dose Vitamin D" ] } } ] } }, "OutcomesModule":{ "PrimaryOutcomeList":{ "PrimaryOutcome":[ { "PrimaryOutcomeMeasure":"Progression Free Survival", "PrimaryOutcomeDescription":"To compare the progression-free survival (PFS) of participants with previously untreated metastatic colorectal cancer randomized to FOLFOX-bevacizumab plus higher-dose vitamin D versus FOLFOX-bevacizumab plus standard-dose vitamin D", "PrimaryOutcomeTimeFrame":"2 years" } ] }, "SecondaryOutcomeList":{ "SecondaryOutcome":[ { "SecondaryOutcomeMeasure":"Overall Survival", "SecondaryOutcomeDescription":"To compare the overall survival (OS) of participants with previously untreated metastatic colorectal cancer randomized to FOLFOX-bevacizumab plus higher-dose vitamin D versus FOLFOX-bevacizumab plus standard-dose vitamin D", "SecondaryOutcomeTimeFrame":"2 years" },{ "SecondaryOutcomeMeasure":"Objective tumor response rate", "SecondaryOutcomeDescription":"To compare the objective tumor response rate (RR) of participants with previously untreated metastatic colorectal cnacer randomized to FOLFOX-bevacizumab plus higher-dose vitamin D versus FOLFOX-bevacizumab plus standard-dose vitamin D", "SecondaryOutcomeTimeFrame":"2 years" },{ "SecondaryOutcomeMeasure":"Safety", "SecondaryOutcomeDescription":"To evaluate and compare the toxicity of adding higher-dose vitamin D versus standard-dose vitamin D to FOLFOX-bevacizumab", "SecondaryOutcomeTimeFrame":"2 years" },{ "SecondaryOutcomeMeasure":"Incidence of vitamin D deficiency", "SecondaryOutcomeDescription":"To evaluate the incidence of vitamin D deficiency in participants with previously untreated metastatic colorectal cancer", "SecondaryOutcomeTimeFrame":"2 years" },{ "SecondaryOutcomeMeasure":"Proportion of participants able to achieve and maintain vitamin D sufficiency", "SecondaryOutcomeDescription":"To compare the proportion of participants who are able to achieve and maintain vitamin D sufficiency with higher-dose vitamin D versus standard-dose vitamin D", "SecondaryOutcomeTimeFrame":"2 years" },{ "SecondaryOutcomeMeasure":"Time course of change in plasma 25-hydroxyvitamin D3 levels", "SecondaryOutcomeDescription":"To compare the time course of change in plasma 25-hydroxyvitamin D3 [25(OH)D] levles in participants randomized to higher-dose vitamin D versus standard-dose vitamin D", "SecondaryOutcomeTimeFrame":"2 years" },{ "SecondaryOutcomeMeasure":"Association between plasma 25(OH)D levels and PFS and OS", "SecondaryOutcomeDescription":"To evaluate the association between plasma 25(OH)D levels and PFS and overall survival", "SecondaryOutcomeTimeFrame":"2 years" } ] } }, "EligibilityModule":{ "EligibilityCriteria":"Inclusion Criteria:\n\nHistologically confirmed adenocarcinoma of the colon or rectum that is metastatic or locally advanced (unresectable)\nMeasurable disease\nKRAS wild-type and KRAS mutant patients are eligible\nNo prior systemic treatment for advanced or metastatic colorectal cancer is allowed\nNo prior radiotherapy to more than 25% of bone marrow\nNo surgery or major biopsy within 4 weeks of randomization\nParaffin-embedded and/or snap-frozen tumor tissue samples must be available\n\nExclusion Criteria:\n\nNot pregnant or breastfeeding\nNo prior chemotherapy, systemic therapy or investigational agent\nNo concurrent use of other anti-cancer therapy\nNo known brain metastases\nNo history of other malignancies except adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, curatively treated lobular or ductal carcinoma in situ of the breast or other cancer curatively treated with no evidence of disease for more than 3 years prior to randomization\nNo regular use of vitamin D supplements greater than 2000 IU per day in the past year\nNo history of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-FU, capecitabine, oxaliplatin, leucovorin, bevacizumab and/or vitamin D3\nNo significant history of bleeding events, pre-existing bleeding diathesis, coagulopathy or gastrointestinal perforation\nNo arterial thrombotic events within 6 months of randomization\nNo serious non-healing wound, ulcer or bone fracture\nNo history of uncontrolled hypertension\nNo clinically significant peripheral neuropathy\nNo predisposing colonic or small bowel disorders in which the symptoms are uncontrolled\nNo uncontrolled seizure disorder or active neurological disease\nNo pre-existing hypercalcemia\nNo known active hyperparathyroid disease\nNo regular use of thiazide diuretics\nNo malabsorption, uncontrolled vomiting or diarrhea\nNo known co-morbid disease that would increase the risk of toxicity\nNo use of chronic oral corticosteroid therapy or any other therapy that can cause vitamin D depletion\nNo clinically significant cardiovascular disease\nNo uncontrolled intercurrent illness\nNo history of any medical or psychiatric condition or addictive disorder or laboratory abnormality that may increase the risks associated with study participation", "HealthyVolunteers":"No", "Gender":"All", "MinimumAge":"18 Years", "StdAgeList":{ "StdAge":[ "Adult", "Older Adult" ] } }, "ContactsLocationsModule":{ "OverallOfficialList":{ "OverallOfficial":[ { "OverallOfficialName":"Kimmie Ng, MD, MPH", "OverallOfficialAffiliation":"Dana-Farber Cancer Institute", "OverallOfficialRole":"Principal Investigator" } ] }, "LocationList":{ "Location":[ { "LocationFacility":"Mountain States Tumor Institute at St. Luke's Regional Medical Center", "LocationCity":"Boise", "LocationState":"Idaho", "LocationZip":"83712", "LocationCountry":"United States" },{ "LocationFacility":"Mountain States Tumor Institute- Fruitland", "LocationCity":"Fruitland", "LocationState":"Idaho", "LocationZip":"83619", "LocationCountry":"United States" },{ "LocationFacility":"Mountain States Tumor Institute - Meridian", "LocationCity":"Meridian", "LocationState":"Idaho", "LocationZip":"83642", "LocationCountry":"United States" },{ "LocationFacility":"Mountain States Tumor Institute- Nampa", "LocationCity":"Nampa", "LocationState":"Idaho", "LocationZip":"83686", "LocationCountry":"United States" },{ "LocationFacility":"Mountain States Tumor Institute- Twin Falls", "LocationCity":"Twin Falls", "LocationState":"Idaho", "LocationZip":"83301", "LocationCountry":"United States" },{ "LocationFacility":"The Robert H. Lurie Comprehensive Cancer Center of Northwestern University", "LocationCity":"Chicago", "LocationState":"Illinois", "LocationCountry":"United States" },{ "LocationFacility":"Massachusetts General Hospital", "LocationCity":"Boston", "LocationState":"Massachusetts", "LocationZip":"02115", "LocationCountry":"United States" },{ "LocationFacility":"Beth Israel Deaconess Medical Center", "LocationCity":"Boston", "LocationState":"Massachusetts", "LocationZip":"02215", "LocationCountry":"United States" },{ "LocationFacility":"Dana-Farber Cancer Institute", "LocationCity":"Boston", "LocationState":"Massachusetts", "LocationZip":"02215", "LocationCountry":"United States" },{ "LocationFacility":"Lowell General Hospital", "LocationCity":"Lowell", "LocationState":"Massachusetts", "LocationCountry":"United States" },{ "LocationFacility":"Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center", "LocationCity":"Milford", "LocationState":"Massachusetts", "LocationCountry":"United States" },{ "LocationFacility":"Newton-Wellesley Hospital", "LocationCity":"Newton", "LocationState":"Massachusetts", "LocationCountry":"United States" },{ "LocationFacility":"Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital", "LocationCity":"South Weymouth", "LocationState":"Massachusetts", "LocationCountry":"United States" },{ "LocationFacility":"New Hampshire Oncology Hematology-P.A.", "LocationCity":"Concord", "LocationState":"New Hampshire", "LocationCountry":"United States" },{ "LocationFacility":"New Hampshire Oncology Hematology-P.A.", "LocationCity":"Hooksett", "LocationState":"New Hampshire", "LocationCountry":"United States" },{ "LocationFacility":"New Hampshire Oncology Hematology-P.A.", "LocationCity":"Laconia", "LocationState":"New Hampshire", "LocationCountry":"United States" },{ "LocationFacility":"Dana-Farber/New Hampshire Oncology-Hematology", "LocationCity":"Londonderry", "LocationState":"New Hampshire", "LocationCountry":"United States" },{ "LocationFacility":"Vanderbilt-Ingram Cancer Center", "LocationCity":"Nashville", "LocationState":"Tennessee", "LocationZip":"37232", "LocationCountry":"United States" } ] } }, "ReferencesModule":{ "ReferenceList":{ "Reference":[ { "ReferencePMID":"30964527", "ReferenceType":"derived", "ReferenceCitation":"Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Miksad R, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin BM, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Ganser C, Wilkinson B, Mackintosh C, Zheng H, Hollis BW, Meyerhardt JA, Fuchs CS. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA. 2019 Apr 9;321(14):1370-1379. doi: 10.1001/jama.2019.2402." } ] } } }, "DerivedSection":{ "MiscInfoModule":{ "VersionHolder":"April 22, 2020" }, "InterventionBrowseModule":{ "InterventionMeshList":{ "InterventionMesh":[ { "InterventionMeshId":"D000014807", "InterventionMeshTerm":"Vitamin D" },{ "InterventionMeshId":"D000004872", "InterventionMeshTerm":"Ergocalciferols" },{ "InterventionMeshId":"D000014815", "InterventionMeshTerm":"Vitamins" },{ "InterventionMeshId":"D000002955", "InterventionMeshTerm":"Leucovorin" },{ "InterventionMeshId":"D000068258", "InterventionMeshTerm":"Bevacizumab" },{ "InterventionMeshId":"D000005472", "InterventionMeshTerm":"Fluorouracil" },{ "InterventionMeshId":"D000077150", "InterventionMeshTerm":"Oxaliplatin" } ] }, "InterventionAncestorList":{ "InterventionAncestor":[ { "InterventionAncestorId":"D000018977", "InterventionAncestorTerm":"Micronutrients" },{ "InterventionAncestorId":"D000078622", "InterventionAncestorTerm":"Nutrients" },{ "InterventionAncestorId":"D000006133", "InterventionAncestorTerm":"Growth Substances" },{ "InterventionAncestorId":"D000045505", "InterventionAncestorTerm":"Physiological Effects of Drugs" },{ "InterventionAncestorId":"D000074322", "InterventionAncestorTerm":"Antineoplastic Agents, Immunological" },{ "InterventionAncestorId":"D000000970", "InterventionAncestorTerm":"Antineoplastic Agents" },{ "InterventionAncestorId":"D000020533", "InterventionAncestorTerm":"Angiogenesis Inhibitors" },{ "InterventionAncestorId":"D000043924", "InterventionAncestorTerm":"Angiogenesis Modulating Agents" },{ "InterventionAncestorId":"D000006131", "InterventionAncestorTerm":"Growth Inhibitors" },{ "InterventionAncestorId":"D000050071", "InterventionAncestorTerm":"Bone Density Conservation Agents" },{ "InterventionAncestorId":"D000077264", "InterventionAncestorTerm":"Calcium-Regulating Hormones and Agents" },{ "InterventionAncestorId":"D000000963", "InterventionAncestorTerm":"Antimetabolites" },{ "InterventionAncestorId":"D000045504", "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action" },{ "InterventionAncestorId":"D000000964", "InterventionAncestorTerm":"Antimetabolites, Antineoplastic" },{ "InterventionAncestorId":"D000007166", "InterventionAncestorTerm":"Immunosuppressive Agents" },{ "InterventionAncestorId":"D000007155", "InterventionAncestorTerm":"Immunologic Factors" },{ "InterventionAncestorId":"D000000931", "InterventionAncestorTerm":"Antidotes" },{ "InterventionAncestorId":"D000020011", "InterventionAncestorTerm":"Protective Agents" },{ "InterventionAncestorId":"D000014803", "InterventionAncestorTerm":"Vitamin B Complex" } ] }, "InterventionBrowseLeafList":{ "InterventionBrowseLeaf":[ { "InterventionBrowseLeafId":"M246", "InterventionBrowseLeafName":"Bevacizumab", "InterventionBrowseLeafAsFound":"Bevacizumab", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M7183", "InterventionBrowseLeafName":"Fluorouracil", "InterventionBrowseLeafAsFound":"Fluorouracil", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M16133", "InterventionBrowseLeafName":"Vitamin D", "InterventionBrowseLeafAsFound":"Vitamin D", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M16141", "InterventionBrowseLeafName":"Vitamins", "InterventionBrowseLeafAsFound":"Vitamin", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M4774", "InterventionBrowseLeafName":"Leucovorin", "InterventionBrowseLeafAsFound":"Leucovorin", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M1674", "InterventionBrowseLeafName":"Oxaliplatin", "InterventionBrowseLeafAsFound":"Oxaliplatin", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M6609", "InterventionBrowseLeafName":"Ergocalciferols", "InterventionBrowseLeafAsFound":"Vitamin D", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M15468", "InterventionBrowseLeafName":"Trace Elements", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M19593", "InterventionBrowseLeafName":"Micronutrients", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M1986", "InterventionBrowseLeafName":"Nutrients", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M1346", "InterventionBrowseLeafName":"Antineoplastic Agents, Immunological", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M20902", "InterventionBrowseLeafName":"Angiogenesis Inhibitors", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M3963", "InterventionBrowseLeafName":"Calcium", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M3980", "InterventionBrowseLeafName":"Calcium, Dietary", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M8372", "InterventionBrowseLeafName":"Hormones", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M2862", "InterventionBrowseLeafName":"Antimetabolites", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M8795", "InterventionBrowseLeafName":"Immunosuppressive Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M8784", "InterventionBrowseLeafName":"Immunologic Factors", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M2831", "InterventionBrowseLeafName":"Antidotes", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M20453", "InterventionBrowseLeafName":"Protective Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M7201", "InterventionBrowseLeafName":"Folic Acid", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M16129", "InterventionBrowseLeafName":"Vitamin B Complex", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"T440", "InterventionBrowseLeafName":"Calciferol", "InterventionBrowseLeafAsFound":"Vitamin D", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"T445", "InterventionBrowseLeafName":"Ergocalciferol", "InterventionBrowseLeafAsFound":"Vitamin D", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"T478", "InterventionBrowseLeafName":"Vitamin D2", "InterventionBrowseLeafAsFound":"Vitamin D", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"T446", "InterventionBrowseLeafName":"Folic Acid", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"T448", "InterventionBrowseLeafName":"Folate", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"T475", "InterventionBrowseLeafName":"Vitamin B9", "InterventionBrowseLeafRelevance":"low" } ] }, "InterventionBrowseBranchList":{ "InterventionBrowseBranch":[ { "InterventionBrowseBranchAbbrev":"ANeo", "InterventionBrowseBranchName":"Antineoplastic Agents" },{ "InterventionBrowseBranchAbbrev":"All", "InterventionBrowseBranchName":"All Drugs and Chemicals" },{ "InterventionBrowseBranchAbbrev":"BDCA", "InterventionBrowseBranchName":"Bone Density Conservation Agents" },{ "InterventionBrowseBranchAbbrev":"Micro", "InterventionBrowseBranchName":"Micronutrients" },{ "InterventionBrowseBranchAbbrev":"Hemat", "InterventionBrowseBranchName":"Hematinics" },{ "InterventionBrowseBranchAbbrev":"Vi", "InterventionBrowseBranchName":"Vitamins" } ] } }, "ConditionBrowseModule":{ "ConditionMeshList":{ "ConditionMesh":[ { "ConditionMeshId":"D000015179", "ConditionMeshTerm":"Colorectal Neoplasms" } ] }, "ConditionAncestorList":{ "ConditionAncestor":[ { "ConditionAncestorId":"D000007414", "ConditionAncestorTerm":"Intestinal Neoplasms" },{ "ConditionAncestorId":"D000005770", "ConditionAncestorTerm":"Gastrointestinal Neoplasms" },{ "ConditionAncestorId":"D000004067", "ConditionAncestorTerm":"Digestive System Neoplasms" },{ "ConditionAncestorId":"D000009371", "ConditionAncestorTerm":"Neoplasms by Site" },{ "ConditionAncestorId":"D000009369", "ConditionAncestorTerm":"Neoplasms" },{ "ConditionAncestorId":"D000004066", "ConditionAncestorTerm":"Digestive System Diseases" },{ "ConditionAncestorId":"D000005767", "ConditionAncestorTerm":"Gastrointestinal Diseases" },{ "ConditionAncestorId":"D000003108", "ConditionAncestorTerm":"Colonic Diseases" },{ "ConditionAncestorId":"D000007410", "ConditionAncestorTerm":"Intestinal Diseases" },{ "ConditionAncestorId":"D000012002", "ConditionAncestorTerm":"Rectal Diseases" } ] }, "ConditionBrowseLeafList":{ "ConditionBrowseLeaf":[ { "ConditionBrowseLeafId":"M16473", "ConditionBrowseLeafName":"Colorectal Neoplasms", "ConditionBrowseLeafAsFound":"Colorectal Cancer", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M9031", "ConditionBrowseLeafName":"Intestinal Neoplasms", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M7469", "ConditionBrowseLeafName":"Gastrointestinal Neoplasms", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M5839", "ConditionBrowseLeafName":"Digestive System Neoplasms", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M7466", "ConditionBrowseLeafName":"Gastrointestinal Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M5838", "ConditionBrowseLeafName":"Digestive System Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M4919", "ConditionBrowseLeafName":"Colonic Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M9027", "ConditionBrowseLeafName":"Intestinal Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M13427", "ConditionBrowseLeafName":"Rectal Diseases", "ConditionBrowseLeafRelevance":"low" } ] }, "ConditionBrowseBranchList":{ "ConditionBrowseBranch":[ { "ConditionBrowseBranchAbbrev":"BC04", "ConditionBrowseBranchName":"Cancers and Other Neoplasms" },{ "ConditionBrowseBranchAbbrev":"BC06", "ConditionBrowseBranchName":"Digestive System Diseases" },{ "ConditionBrowseBranchAbbrev":"All", "ConditionBrowseBranchName":"All Conditions" } ] } } } } } }